|
|
|
| Webinar: Early Developability Assessment for Antibody Based Therapeutics | De-risk multi-specific antibody development with Lonza’s integrated toolbox approach. Learn how in silico and in vitro screening can uncover developability, manufacturability, potency, and immunosafety risks early. Discover how smarter candidate selection, stronger early data, and scalable expression systems can help accelerate timelines, reduce downstream setbacks, improve lead prioritization, and support confident clinical advancement in a competitive biologics landscape. Click here to learn more. |
|
|
|
| De-Risking A Novel Valve Component With Standard Syringe Systems | Article | By Marc Flippe and Sophie Lelias, BD Medical - Pharmaceutical Systems | A novel valve provides dual‑chamber functionality within standard syringes, keeping two liquid drugs separated until injection while reducing development risk through advanced modeling. |
|
|
| Beyond Solid Phase Synthesis | Webinar | Asymchem | Explore how enzymatic methods, real-time analytics, and AI optimization enhance long-sequence TIDES, improving control, speeding timelines, and supporting sustainable production. |
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Manda Pasarkar, Global Regulatory Affairs, CMC Head, Sanofi, has overseen global, multi-billion-dollar portfolios of products from early development to commercialization. She spoke with Chief Editor Louis Garguilo on her outsourcing strategy and philosophy. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Precision Control In Animal‑Free Raw Materials | Infographic | Nu-Tek Biosciences | Animal‑free raw materials offer adjustable attributes, controlled manufacturing, and consistent nutrient profiles, ensuring reliable performance and customizable solutions across multiple production processes. |
|
|
|
|
|
|
| Scalable Protein Expression With Technology | Webinar | Lonza | Uncover the benefits, including speed, simple fermentation regimes, and robust, scalable processes that can be tuned according to the specific objectives of a program. |
|
|
|
|
|
|
|
|
|
API Sterilization | Curia | Leverage advanced aseptic processing and Quality Risk Management–driven controls that help ensure sterile-grade APIs when terminal sterilization is not a viable option. |
|
|
Two Sites, One Standard of Excellence | Jubilant HollisterStier | Secure your supply chain with a trusted partner in sterile manufacturing. Discover a dual-site strategy that offers crucial redundancy, high regulatory confidence, and an approach to efficient tech transfer. |
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|